Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

A Study of NGM621 in Participants With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT04465955 Org: User:
Start: 07/22/20 End: 08/16/22 Due: 08/16/23

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03392116 Org: User:
Start: 01/29/18 End: 03/11/19 Due: 03/11/20

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT02704364 Org: User:
Start: 03/31/16 End: 06/30/17 Due: 06/30/18

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT02443116 Org: User:
Start: 07/31/15 End: 01/17/20 Due: 01/17/21

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05311618 Org: User:
Start: 05/11/22 End: 06/30/25 Due: 06/30/26

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Phase: N/A Priority: Normal
NCT ID: NCT07033026 Org: User:
Start: 06/30/25 End: 12/31/27 Due: 12/31/28

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02135536 Org: User:
Start: 05/31/14 End: 02/29/16 Due: 02/28/17

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Phase: N/A Priority: Normal
NCT ID: NCT06654726 Org: User:
Start: 10/21/24 End: 03/18/25 Due: 03/18/26

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05215574 Org: User:
Start: 03/31/22 End: 03/31/26 Due: 03/31/27

Phase 1 Study of NGM313 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT02708576 Org: User:
Start: 02/29/16 End: 04/30/17 Due: 04/30/18

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Phase: N/A Priority: Normal
NCT ID: NCT02649062 Org: User:
Start: 12/31/15 End: 01/31/17 Due: 01/31/18

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT01776528 Org: User:
Start: 01/31/13 End: 07/31/13 Due: 07/31/14

Study of NGM313 in Obese Participants

Phase: N/A Priority: Normal
NCT ID: NCT03298464 Org: User:
Start: 09/11/17 End: 07/17/18 Due: 07/17/19

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04582318 Org: User:
Start: 11/09/20 End: 03/11/21 Due: 03/11/22

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT04179630 Org: User:
Start: 11/08/19 End: 12/14/19 Due: 12/14/20

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01943045 Org: User:
Start: 09/30/13 End: 09/30/14 Due: 09/30/15

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04828265 Org: User:
Start: 04/13/21 End: 07/06/21 Due: 07/06/22

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Phase: N/A Priority: Normal
NCT ID: NCT03912532 Org: User:
Start: 05/16/19 End: 03/29/21 Due: 03/29/22

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02026401 Org: User:
Start: 02/28/14 End: 12/31/14 Due: 12/31/15

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04913337 Org: User:
Start: 06/09/21 End: 07/31/25 Due: 07/31/26

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Phase: N/A Priority: Normal
NCT ID: NCT04210245 Org: User:
Start: 03/23/20 End: 02/23/23 Due: 02/23/24

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT04823702 Org: User:
Start: 04/01/21 End: 11/19/21 Due: 11/19/22

Study of NGM621 in Participants With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT04014777 Org: User:
Start: 07/26/19 End: 05/27/20 Due: 05/27/21

Study of NGM395 in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04187339 Org: User:
Start: 02/13/20 End: 04/22/21 Due: 04/22/22

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04068896 Org: User:
Start: 10/16/19 End: 01/08/24 Due: 01/08/25